
Commentary|Videos|June 5, 2024
Dr Garrido-Castro on Sacituzumab Govitecan With or Without Pembrolizumab in Metastatic HR+/HER2– Breast Cancer
Author(s)Ana Christina Garrido-Castro, MD
Ana Christina Garrido-Castro, MD, on sacituzumab govitecan with/without pembrolizumab in metastatic hormone receptor–positive, HER2-negative breast cancer.
Advertisement
Ana Christina Garrido-Castro, MD, medical oncologist, co-director, Triple-Negative Breast Cancer Working Group, Dana-Farber Cancer Institute, and assistant professor of medicine, Harvard Medical School, discusses findings from the phase 2 SACI-IO HR+ trial (NCT04448886) evaluating sacituzumab govitecan-hziy (Trodelvy) with or without pembrolizumab (Keytruda) in patients with metastatic hormone receptor–positive, HER2-negative breast cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma
5



































